Eli Lilly hikes dividend by 15.4%

On December 9, 2024, Eli Lilly (LLY) announced a 15% dividend increase together with a new $15 billion buyback program. This marks the 7th consecutive year with a 15% increase by LLY.

Eli Lilly declared a dividend for the first quarter of 2025 of $1.50 per share. The dividend is payable on March 10, 2025, to shareholders of record at the close of business on February 14, 2025. At a stock price of $796 the dividend yield for LLY is 0.75%.

"As Lilly has entered into a period of rapid growth, our capital allocation priorities remain the same. We will continue to focus on supporting new launches, expanding our manufacturing capacity, and advancing our pipeline through research and development and business development," said Lucas Montarce, Lilly executive vice president and chief financial officer. "However, given the strong growth profile of the company, we're also increasing the amount of capital we plan to return to shareholders. We expect to execute this program over the next three years."

Eli Lilly has now raised its dividend by 15% for 7 consecutive years, leading all other big pharmaceutical companies in the United States in terms of dividend growth.

Eli Lilly and Company is a pharmaceutical firm that discovers, develops, manufactures, and markets human pharmaceutical products. Their portfolio includes diabetes and cardiometabolic treatments like Basaglar, Humalog, Mounjaro, Trulicity, and Zepbound. In oncology, they offer Alimta, Retevmo, Tyvyt, and Verzenio. Their immunology products include Ebglyss, Olumiant, Omvoh, and Taltz, while their neuroscience offerings feature Cymbalta and Emgality. Additionally, they produce Cialis and Forteo. Eli Lilly operates manufacturing and distribution facilities in the U.S., Puerto Rico, Europe, and Asia. Through their subsidiary, POINT Biopharma Global Inc., they are involved in radiopharmaceuticals and radioligand therapies, and are developing MORF-057 for inflammatory bowel disease.